VivoSeq
Oncology

Hormone-Receptor-Positive Breast Cancer

13

Pipeline Programs↗

5

Active Trials↗

9

Companies Involved↗

Hormone-receptor-positive Breast Cancer is an emerging landscape with 13 programs across 9 companies. The most active players are BeOne Medicines, Fresenius Kabi Oncology Ltd., BeiGene.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

15/100

Mech. Concentration

22/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

BeOne Medicines

1 program

Phase 1F

Fresenius Kabi Oncology Ltd.

1 program

Phase 1BeiGene logo

BeiGene

1 program

Phase 1Regeneron logo

Regeneron

1 program

Phase 1Novartis logo

Novartis

2 programs

Phase 2Eli Lilly logo

Eli Lilly

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

87%

Small molecule

13 of 15 classified programs — the dominant modality here.

13%ALL OTHERSMonoclonal antibody17%Peptide17%

Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 100% of 15 pipeline programs.

Analysis

Trial Status

6

clinical trials

Recruiting4 · 67%
Not yet recruiting1 · 17%
Completed1 · 17%

Clinical Trials

Trial Activity

6 trials

CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment of Breast Cancer: ctDNA-Guided Personalized Therapy
Recruiting·PPeking University People's Hospital·Phase 2·NCT07366112·158 enrolled
A Prospective, Multicenter, Randomized, Open-Label Phase II Study of ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
Recruiting·PPeking University People's Hospital·Phase 2·NCT06970912·393 enrolled
A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-21447 (a Bcl-2 Inhibitor) Combinations for Patients With HR+/HER2- Metastatic Breast Cancer
Recruiting·BBeOne Medicines·Phase 1·NCT06756932·120 enrolled
A Modular, Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 as Monotherapy and in Combination in Patients With Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Recruiting·EEllipses Pharma·Preclinical·NCT05573126·95 enrolled
Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial
Not yet recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 2·NCT07676331·168 enrolled
A Phase I Trial of Capecitabine in Combination With Cemiplimab in Patients With Hormone Receptor Positive Metastatic Breast Cancer
Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT05064085·13 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)